33 results on '"Holdenrieder Stefan"'
Search Results
2. Quantification of ventricular stress in univentricular hearts during early childhood using age-independent zlog-NT-proBNP
- Author
-
Palm, Jonas, Ono, Masamichi, Niedermaier, Carolin, Hörer, Jürgen, Hoffmann, Georg, Holdenrieder, Stefan, Klawonn, Frank, and Ewert, Peter
- Published
- 2024
- Full Text
- View/download PDF
3. Prognostic value of glomerular function estimated by Cockcroft-Gault creatinine clearance, MDRD-4, CKD-EPI and European Kidney Function Consortium equations in patients with acute coronary syndromes
- Author
-
Ndrepepa, Gjin, Holdenrieder, Stefan, Neumann, Franz-Josef, Lahu, Shqipdona, Cassese, Salvatore, Joner, Michael, Xhepa, Erion, Kufner, Sebastian, Wiebe, Jens, Laugwitz, Karl-Ludwig, Gewalt, Senta, Schunkert, Heribert, and Kastrati, Adnan
- Published
- 2021
- Full Text
- View/download PDF
4. The prostate health index (PHI) density: Are there advantages over PHI or over the prostate-specific antigen density?
- Author
-
Garrido, Manuel M., Ribeiro, Ruy M., Pinheiro, Luís C., Holdenrieder, Stefan, and Guimarães, João T.
- Published
- 2021
- Full Text
- View/download PDF
5. Satellite 2 repeat DNA in blood plasma as a candidate biomarker for the detection of cancer
- Author
-
Özgür, Emre, Mayer, Zsuzsanna, Keskin, Metin, Yörüker, Ebru E., Holdenrieder, Stefan, and Gezer, Ugur
- Published
- 2021
- Full Text
- View/download PDF
6. Inverse association of alanine aminotransferase within normal range with prognosis in patients with coronary artery disease
- Author
-
Ndrepepa, Gjin, Holdenrieder, Stefan, Colleran, Roisin, Cassese, Salvatore, Xhepa, Erion, Fusaro, Massimiliano, Laugwitz, Karl-Ludwig, Schunkert, Heribert, and Kastrati, Adnan
- Published
- 2019
- Full Text
- View/download PDF
7. Methods for isolation of cell-free plasma DNA strongly affect DNA yield
- Author
-
Fleischhacker, Michael, Schmidt, Bernd, Weickmann, Sabine, Fersching, Debora M.I., Leszinski, Gloria S., Siegele, Barbara, Stötzer, Oliver J., Nagel, Dorothea, and Holdenrieder, Stefan
- Published
- 2011
- Full Text
- View/download PDF
8. Prognostic value of De Ritis ratio with aspartate aminotransferase and alanine aminotransferase within the reference range.
- Author
-
Ndrepepa, Gjin, Holdenrieder, Stefan, and Kastrati, Adnan
- Subjects
- *
ASPARTATE aminotransferase , *ALANINE aminotransferase , *PROGNOSIS , *CARDIOVASCULAR diseases risk factors , *CORONARY artery disease - Abstract
• Elevated De Ritis ratio with AST and ALT activity in the reference range has prognostic value. • De Ritis ratio with AST and ALT activity in the reference range predicts 3-year all-cause, cardiac and noncardiac mortality. • De Ritis ratio provides prognostic information on top of cardiovascular risk factors. Whether aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (De Ritis ratio) with AST and ALT activities within the reference range has prognostic value is unknown. This study included 3392 patients with stable coronary artery disease and AST and ALT activities within the reference range. Patients are categorized in groups according to tertiles of the De Ritis ratio: a group with De Ritis ratio in the 1st tertile (De Ritis ratio: 0.22 to 0.81; n = 1131), a group with De Ritis ratio in the 2nd tertile (De Ritis ratio: >0.81 to 1.09; n = 1130) and a group with De Ritis ratio in the 3rd tertile (De Ritis ratio: >1.09 to 3.40; n = 1131). The primary endpoint was 3-year mortality. The mean value of De Ritis ratio was 1.00 ± 0.39 (range: 0.22–3.40). Overall, there were 234 deaths at 3 years: 43 deaths in patients of 1st tertile, 75 deaths in patients of 2nd tertile and 116 deaths in patients of 3rd tertile of De Ritis ratio (Kaplan-Meier estimates of 3-year mortality, 4.4 %, 7.8 % and 12.5 %, respectively; (adjusted hazard ratio = 1.24, 95 % confidence interval 1.12 to 1.38; P < 0.001 for 1 unit higher De Ritis ratio). The C-statistic of the risk prediction model for mortality with baseline demographical and clinical variables without De Ritis ratio was 0.803 [0.774–0.832] and it increased to 0.810 [0.782–0.839] after inclusion of De Ritis ratio into the model (P = 0.038). An elevated De Ritis ratio with aminotransferase levels within the reference range was associated with the increased risk of mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease
- Author
-
Deligezer, Ugur, Yaman, Fulya, Darendeliler, Emin, Dizdar, Yavuz, Holdenrieder, Stefan, Kovancilar, Müge, and Dalay, Nejat
- Published
- 2010
- Full Text
- View/download PDF
10. Prognostic value of De Ritis ratio in patients with acute myocardial infarction.
- Author
-
Ndrepepa, Gjin, Holdenrieder, Stefan, and Kastrati, Adnan
- Subjects
- *
MYOCARDIAL infarction , *ASPARTATE aminotransferase , *PROGNOSIS , *PERCUTANEOUS coronary intervention , *ALANINE aminotransferase - Abstract
• De Ritis ratio predicts 3-year all-cause mortality after acute myocardial infarction. • De Ritis ratio predicts 3-year cardiac mortality after acute myocardial infarction. • De Ritis ratio predicts 30-day risk of bleeding after percutaneous coronary intervention. • De Ritis ratio has a moderate sensitivity regarding prediction of mortality. The association between aspartate aminotransferase to alanine aminotransferase ratio (De Ritis ratio) and prognosis of patients with acute myocardial infarction (AMI) remains poorly investigated. This study included 3000 patients with AMI undergoing percutaneous coronary intervention. Patients were categorized in groups according to tertiles of the De Ritis ratio: tertile 1 (De Ritis ratio < 1.11; 905 patients), tertile 2 (De Ritis ratio 1.11 to 1.95; 1003 patients) and tertile 3 (De Ritis ratio > 1.95; 1002 patients). The primary endpoint was 3-year all-cause mortality. At 3 years, all-cause deaths occurred in 487 patients: 119 deaths (13.2%) in patients of 1st tertile, 164 deaths (17.8%) in patients of 2nd tertile and 204 deaths (21.9%) in patients of 3rd tertile of the De Ritis ratio (adjusted hazard ratio [HR] = 1.16, 95% confidence interval [CI] 1.02 to 1.31], P = 0.023 per unit increment in the logarithmic scale of the De Ritis ratio); cardiac deaths occurred in 328 patients: 76 deaths (8.2%) in patients of 1st tertile, 110 deaths (12.0%) in patients of 2nd tertile and 142 deaths (15.4%) in patients of 3rd tertile of the De Ritis ratio (adjusted HR = 1.20 [1.04–1.40], P = 0.014 per unit increment in the logarithmic scale of De Ritis ratio). The C-statistic of the multivariable model(s) with baseline data without and with De Ritis ratio was 0.822 [0.805–0.839] and 0.823 [0.805–0.840], (P = 0.419) for all-cause mortality and 0.831[0.811–0.852] and 0.832 [0.811–0.853], P = 0.621) for cardiac mortality. In patients with AMI, elevated De Ritis ratio was associated with increased risk of 3-year mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Alkaline phosphatase and prognosis in patients with diabetes mellitus and ischemic heart disease.
- Author
-
Ndrepepa, Gjin, Holdenrieder, Stefan, Xhepa, Erion, Cassese, Salvatore, Lahu, Shqipdona, Kufner, Sebastian, and Kastrati, Adnan
- Subjects
- *
MYOCARDIAL ischemia , *CORONARY disease , *ALKALINE phosphatase , *PEOPLE with diabetes , *DIABETES - Abstract
• ALP predicts 3-year mortality in patients with diabetes mellitus and ischemic heart disease. • Low and high ALP activity levels were associated with increased risk of mortality. • Impaired renal function and elevated C-reactive protein correlated with higher ALP activity. The association between alkaline phosphatase (ALP) and mortality in patients with diabetes mellitus (DM) and ischemic heart disease (IHD) remains poorly investigated. The study included 1426 patients with DM and IHD who underwent percutaneous coronary intervention. Patients were divided in groups according to tertiles of ALP activity: a group with ALP activity in 1st tertile (ALP activity: 20.8–65.0 U/L; n = 478), a group with ALP activity in 2nd tertile (ALP activity: 65.1–87.0 U/L; n = 473) and a group with ALP activity in 3rd tertile (ALP activity: 87.1–1520 U/L; n = 475). The primary endpoint was 3-year all-cause mortality. At 3 years, all-cause deaths occurred in 182 patients: 50 deaths (12.4%) in patients of 1st tertile, 47 deaths (11.7%) in patients of 2nd tertile and 85 deaths (20.8%) in patients of 3rd tertile of ALP activity (adjusted hazard ratio [HR] = 1.20, 95% confidence interval [CI] 1.02 to 1.42, P = 0.031); cardiac deaths occurred in 110 patients: 28 deaths (7.0%) in patients of 1st tertile, 30 deaths (7.6%) in patients of 2nd tertile and 52 deaths (12.7%) in patients of 3rd tertile of ALP activity (adjusted HR = 1.27 [1.04–1.56], P = 0.021, with both risk estimates calculated for unit increment in the log scale of ALP activity). The C-statistic of the multivariable model with baseline data without and with ALP was 0.787 [0.750–0.818] and 0.804 [0.757–0.851], (P = 0.575) for all-cause mortality and 0.832 [0.798–0.864] and 0.876 [0.833–0.918], (P = 0.115) for cardiac mortality. In patients with DM and IHD, elevated ALP activity was associated with increased risk of 3-year mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Time courses of HMGB1 and other inflammatory markers after generalized convulsive seizures
- Author
-
Nass, Robert D., Wagner, Marcus, Surges, Rainer, and Holdenrieder, Stefan
- Published
- 2020
- Full Text
- View/download PDF
13. Moving Forward on Tumor Pathology Research Reporting: A Guide for Pathologists From the World Health Organization Classification of Tumors Living Evidence Gap Map by Tumour Type Group.
- Author
-
Colling, Richard, Indave, Iciar, Del Aguilla, Javier, Cierco Jimenez, Ramon, Campbell, Fiona, Chechlinska, Magdalena, Kowalewska, Magdalena, Holdenrieder, Stefan, Trulson, Inga, Worf, Karolina, Pollán, Marina, Plans-Beriso, Elena, Pérez-Gómez, Beatriz, Craciun, Oana, García-Ovejero, Ester, Michalek, Irmina Maria, Maslova, Kateryna, Rymkiewicz, Grzegorz, Didkowska, Joanna, and Tan, Puay Hoon
- Published
- 2024
- Full Text
- View/download PDF
14. Predicting Major Adverse Cardiovascular Events in Children With Age-Adjusted NT-proBNP.
- Author
-
Palm, Jonas, Holdenrieder, Stefan, Hoffmann, Georg, Hörer, Jürgen, Shi, Ruibing, Klawonn, Frank, and Ewert, Peter
- Subjects
- *
CARDIOVASCULAR diseases , *ARTIFICIAL blood circulation , *PROGNOSIS , *CONGENITAL heart disease , *REFERENCE values - Abstract
Background: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is frequently used as a valuable prognostic biomarker in cardiac diseases. In children, however, it has not been established because of its strong age dependency. To overcome this obstacle, we recently introduced the zlog value of N-terminal pro-B-type natriuretic peptide (zlog-proBNP) as an age-adjusted reference.Objectives: This study evaluates the prognostic power of zlog-proBNP for the occurrence of major adverse cardiovascular events (MACE) throughout childhood in patients with congenital heart diseases (CHD).Methods: A total of 910 children with CHD (median age 5 months; range 0.0-18.0 years) were included. MACE was defined as death, resuscitation, mechanical circulatory support, or hospitalization caused by cardiac decompensation. Because the physiological NT-proBNP concentration decreases significantly during childhood, zlog values were applied for an age-independent evaluation.Results: MACE occurred in 138 children during a median follow-up of 6 months (range 1 day to 7.6 years). High zlog-proBNP values (>+3.0) were most strongly associated with adverse events (n = 93; adjusted HR: 21.1; 95% CI: 2.9-154.2; P < 0.001). Among all evaluated indicators, zlog-proBNP was the best predictor for MACE (adjusted HR: 1.52; 95% CI: 1.31-1.76; P < 0.001) along with age and predictively superior to absolute NT-proBNP values. A cutoff value of +1.96 (age-independent upper limit of the physiological NT-proBNP concentration) achieved a negative predictive value of >96%.Conclusions: Zlog-proBNP overcomes the strong age dependency of NT-proBNP and is a powerful prognostic marker for age-independent exclusion and prediction of MACE in children with CHD. We therefore expect zlog-proBNP to play a pivotal role in the future management of children with heart diseases. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
15. Aspartate aminotransferase and mortality in patients with ischemic heart disease.
- Author
-
Ndrepepa, Gjin, Holdenrieder, Stefan, Cassese, Salvatore, Xhepa, Erion, Fusaro, Massimiliano, Laugwitz, Karl-Ludwig, Schunkert, Heribert, and Kastrati, Adnan
- Abstract
Background and Aims: Evidence on the association between aspartate aminotransferase (AST) activity and mortality of patients with ischemic heart disease (IHD) is limited. We investigated whether there is an association between AST activity and mortality in IHD patients.Methods and Results: The study included 6857 patients with coronary angiography-proven IHD and AST activity within the reference range. AST activity measurements were available in all patients. The primary outcome was 3-year cardiac mortality. Patients were categorized in groups according to the AST activity tertiles: a group with AST within the 1st tertile (AST < 17.0 U/L), a group with AST within the 2nd tertile (AST > 17-24.5 U/L) and a group with AST within the 3rd tertile (AST > 24.5 U/L). Cardiac death (n = 297) occurred in 109, 69 and 119 patients in the 1st to 3rd AST tertiles (Kaplan-Meier estimates of mortality: 5.3%, 3.6% and 5.9%; univariable hazard ratio [HR] = 1.75, 95% confidence interval [CI] 1.30-2.36, P < 0.001 for tertile 3 vs. 2; HR = 1.13 [0.87-1.46], P = 0.370 for tertile 3 vs. 1; and HR = 0.65 [0.48-0.87], P = 0.004 for tertile 2 vs. 1). The association between AST and cardiac mortality was U-shaped. AST values <15 U/L (HR = 1.118 [1.009-1.238]) and >23 U/L (HR = 1.029 [1.003-1.056]) were associated with higher cardiac mortality compared with the reference value (21 U/L). After adjustment, the association between AST and cardiac mortality was attenuated (P = 0.133) but remained non-linear (P = 0.047).Conclusions: In patients with IHD, AST activity was associated with the risk of cardiac mortality with a U-shaped relationship. After adjustment, the association between AST and mortality was attenuated. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
16. SARS-CoV-2 antibody testing—questions to be asked.
- Author
-
Özçürümez, Mustafa K., Ambrosch, Andreas, Frey, Oliver, Haselmann, Verena, Holdenrieder, Stefan, Kiehntopf, Michael, Neumaier, Michael, Walter, Michael, Wenzel, Folker, Wölfel, Roman, and Renz, Harald
- Abstract
Severe acute respiratory syndrome coronavirus 2 infection and development of coronavirus disease 2019 presents a major health care challenge of global dimensions. Laboratory diagnostics of infected patients, and the assessment of immunity against severe acute respiratory syndrome coronavirus 2, presents a major cornerstone in handling the pandemic. Currently, there is an increase in demand for antibody testing and a large number of tests are already marketed or are in the late stage of development. However, the interpretation of test results depends on many variables and factors, including sensitivity, specificity, potential cross-reactivity and cross-protectivity, the diagnostic value of antibodies of different isotypes, and the use of antibody testing in identification of acutely ill patients or in epidemiological settings. In this article, the recently established COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) addresses these issues on the basis of currently available data sets in this rapidly moving field. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Differential Prognostic Value of Galectin-3 According to Carbohydrate Antigen 125 Levels in Transcatheter Aortic Valve Implantation.
- Author
-
Rheude, Tobias, Pellegrini, Costanza, Núñez, Julio, Joner, Michael, Trenkwalder, Teresa, Mayr, N. Patrick, Holdenrieder, Stefan, Bodi, Vicent, Koenig, Wolfgang, Kasel, Albert M., Schunkert, Heribert, Kastrati, Adnan, Hengstenberg, Christian, and Husser, Oliver
- Abstract
Copyright of Revista Española de Cardiología (18855857) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF
18. A New Hierarchy of Research Evidence for Tumor Pathology: A Delphi Study to Define Levels of Evidence in Tumor Pathology.
- Author
-
Colling, Richard, Indave, Iciar, del Aguila, Javier, Jimenez, Ramon Cierco, Campbell, Fiona, Chechlińska, Magdalena, Kowalewska, Magdalena, Holdenrieder, Stefan, Trulson, Inga, Worf, Karolina, Pollán, Marina, Plans-Beriso, Elena, Pérez-Gómez, Beatriz, Craciun, Oana, García-Ovejero, Ester, Michałek, Irmina Maria, Maslova, Kateryna, Rymkiewicz, Grzegorz, Didkowska, Joanna, and Tan, Puay Hoon
- Published
- 2024
- Full Text
- View/download PDF
19. Prognostic value of alkaline phosphatase in patients with acute coronary syndromes.
- Author
-
Ndrepepa, Gjin, Holdenrieder, Stefan, Xhepa, Erion, Cassese, Salvatore, Fusaro, Massimiliano, Laugwitz, Karl-Ludwig, Schunkert, Heribert, and Kastrati, Adnan
- Subjects
- *
ACUTE coronary syndrome , *ALKALINE phosphatase , *PERCUTANEOUS coronary intervention , *HEART disease related mortality , *RECEIVER operating characteristic curves , *CONFIDENCE intervals , *PROGNOSIS - Abstract
Objectives The objective of the study was to investigate the association between alkaline phosphatase (AP) activity and prognosis of patients with acute coronary syndrome (ACS). Design and methods The study included 2134 patients with ACS undergoing percutaneous coronary intervention. All included patients had baseline AP measurements available. The receiver operating characteristic curve analysis showed that the best cut-off of AP for mortality prediction was 98.0 U/L. Using this cut-off, patients were divided into two groups: a group with AP > 98.0 U/L ( n = 493) and a group with AP ≤ 98.0 U/L ( n = 1641). The primary endpoint was 3-year mortality. Results Overall, there were 229 deaths over the follow-up: 90 deaths among patients with an AP > 98.0 U/L and 139 deaths among patients with an AP ≤ 98.0 U/L (Kaplan-Meier estimates of 3-year total mortality, 19.5% and 9.3%, respectively; adjusted hazard ratio [HR] = 1.37, 95% confidence interval [CI] 1.10–1.70, P = 0.004 for each unit higher log AP). Cardiac deaths occurred in 157 patients: 66 deaths among patients with an AP > 98.0 U/L and 91 deaths among patients with an AP ≤ 98.0 U/L (Kaplan-Meier estimates of 3-year cardiac mortality, 14.3% and 6.0%, respectively; adjusted HR = 1.32 [1.02–1.70], P = 0.033, for each unit higher log AP). The C-statistic of the multivariable model with baseline variables was 0.836 [0.807–0.866] and it increased to 0.842 [0.814–0.874] after inclusion of AP ( P = 0.045). Conclusions In patients presenting with an ACS and treated with percutaneous coronary intervention, elevated AP activity is associated with increased risk of subsequent mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
20. Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.
- Author
-
Wilhelm, Martin, Mueller, Lothar, Miller, M. Craig, Link, Karin, Holdenrieder, Stefan, Bertsch, Thomas, Kunzmann, Volker, Stoetzer, Oliver J., Suttmann, Ingo, Braess, Jan, Birkmann, Josef, Roessler, Max, Moritz, Berta, Kraff, Stefanie, Salamone, Salvatore J., and Jaehde, Ulrich
- Published
- 2016
- Full Text
- View/download PDF
21. Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
- Author
-
Yörüker, Ebru E., Holdenrieder, Stefan, and Gezer, Ugur
- Subjects
- *
COLON cancer diagnosis , *COLON cancer prognosis , *BIOMARKERS , *INVASIVE diagnosis , *BIOPSY , *COLON cancer treatment , *TERATOCARCINOMA , *COLONOSCOPY - Abstract
The global burden of colorectal cancer (CRC)-associated morbidity and mortality is increasing, in part due to a lack of early detection. Direct structural examination techniques, such as colonoscopy, are invasive and can therefore affect the willingness of patients to participate in screening. Recently, the use of “liquid biopsy” has gained considerable attention as a novel source of biomarkers. Blood-based biomarkers could prove to be practical tools for CRC detection, as the monitoring of biomarkers in biological fluids offers many advantages, including minimal invasiveness and easy accessibility. Biomarkers with high specificity and sensitivity can enable the detection of CRC at an early stage, thereby improving prognosis, prediction of treatment response, and recurrence risk. In this review, we summarize that the biomarkers currently thought to have potential for the early detection and monitoring of CRC, including circulating tumor cells, DNA, RNA and proteins. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
22. Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement.
- Author
-
Sinning, Jan-Malte, Wollert, Kai C., Sedaghat, Alexander, Widera, Christian, Radermacher, Marie-Caroline, Descoups, Claire, Hammerstingl, Christoph, Weber, Marcel, Stundl, Anja, Ghanem, Alexander, Widder, Julian, Vasa-Nicotera, Mariuca, Mellert, Fritz, Schiller, Wolfgang, Bauersachs, Johann, Zur, Berndt, Holdenrieder, Stefan, Welz, Armin, Grube, Eberhard, and Pencina, Michael J.
- Abstract
Background: Up to 50% of the patients still die or have to be rehospitalized during the first year after transcatheter aortic valve replacement (TAVR). This emphasizes the need for more strategic patient selection. The aim of this prospective observational cohort study was to compare the prognostic value of risk scores and circulating biomarkers to predict all-cause mortality and rehospitalization in patients undergoing TAVR.Methods: We calculated the hazard ratios and C-statistics (area under the curve [AUC]) of 4 risk scores (logistic European System for Cardiac Operative Risk Evaluation [EuroSCORE], EuroSCORE II, Society of Thoracic Surgeons predicted risk of mortality, and German aortic valve score) and 5 biomarkers of inflammation and/or myocardial dysfunction (high-sensitivity C-reactive protein, growth differentiation factor (GDF)-15, interleukin-6, interleukin-8, and N-terminal pro-B-type natriuretic peptide) for the risk of death (n = 80) and the combination of death or rehospitalization (n = 132) during the first year after TAVR in 310 consecutive TAVR patients.Results: The EuroSCORE II and GDF-15 had the strongest predictive value for 1-year mortality (EuroSCORE II, AUC 0.711; GDF-15, AUC 0.686) and for the composite end point (EuroSCORE II, AUC 0.690; GDF-15, AUC 0.682). When added to the logistic EuroSCORE and EuroSCORE II, GDF-15 enhanced the prognostic performance of the score and enabled substantial reclassification of patients. Combinations of increasing tertiles of the logistic EuroSCORE or EuroSCORE II and GDF-15 allowed the stratification of the patients into subgroups with mortality rates ranging from 4.0% to 49.1% and death/rehospitalization rates ranging from 15.3% to 68.4%.Conclusions: Our study identified GDF-15 in addition to the logistic EuroSCORE and the EuroSCORE II as the most promising predictors of a poor outcome after TAVR. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
23. Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China.
- Author
-
Korse, Catharina M., Holdenrieder, Stefan, Zhi, Xiu-yi, Zhang, Xiaotong, Qiu, Ling, Geistanger, Andrea, Lisy, Marcus-Rene, Wehnl, Birgit, van den Broek, Daan, Escudero, José M., Standop, Jens, Hu, Mu, and Molina, Rafael
- Subjects
- *
PEPTIDES , *IMMUNOASSAY , *LUNG cancer , *KIDNEY disease risk factors , *STATISTICAL correlation - Abstract
Background We performed a multicenter evaluation of the Elecsys® progastrin-releasing peptide (ProGRP) immunoassay in Europe and China. Methods The assay was evaluated at three European and two Chinese sites by imprecision, stability, method comparison and differentiation potential in lung cancer. Results Intermediate imprecision across five analyte concentrations ranged from 2.2% to 6.0% coefficient of variation. Good stability for plasma and serum samples was shown for various storage conditions. There was excellent correlation between the Elecsys® and ARCHITECT assays in plasma (slope 1.02, intercept − 2.72 pg/mL). The Elecsys® assay also showed good correlation between serum and plasma samples (slope 0.93, intercept 2.35 pg/mL; correlation coefficient 0.97). ProGRP differentiated small-cell and non-small-cell lung cancer (NSCLC; area under the curve 0.90, 95% CI 0.87–0.93; 78.3% sensitivity, 95% specificity; at 84 pg/mL), with no relevant effects of ethnicity, age, gender or smoking. Median ProGRP concentrations were low in benign diseases (38 pg/mL), other malignancies (40 pg/mL) or NSCLC (39 pg/mL), except chronic kidney disease above stage 3 (> 100 pg/mL). Conclusions Increased stability of the Elecsys® ProGRP assay in serum and plasma offers clear benefits over existing assays. This first evaluation of a ProGRP assay in China demonstrated comparable differentiation potential among different ethnicities. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. Increased N-terminal Pro-B-Type Natriuretic Peptide during Extracorporeal Life Support Is Associated with Poor Outcome in Neonates with Congenital Diaphragmatic Hernia.
- Author
-
Bo, Bartolomeo, Balks, Julian, Gries, Kristina, Holdenrieder, Stefan, Mueller, Andreas, and Kipfmueller, Florian
- Abstract
Objectives: To evaluate the prognostic information derived from the daily measurements of N-terminal pro-B-type natriuretic peptide (proBNP) in neonates with congenital diaphragmatic hernia undergoing extracorporeal life support (ECLS).Study Design: Plasma proBNP was prospectively measured daily during the first week of ECLS using an electrochemiluminescence immunoassay. Patients (n = 63) were allocated according to outcome: survivors (group 1, n = 35); nonsurvivors with successful weaning (defined as survival for >12 hours after ECLS discontinuation) (group 2, n = 16); nonsurvivors with unsuccessful weaning (group 3, n = 12). ProBNP kinetics were compared using Kruskal-Wallis testing and correlated with pulmonary hypertension and cardiac dysfunction on echocardiography using the Spearman correlation coefficient.Results: Infants in group 3 presented significantly higher proBNP values from day 3 to day 6 compared with group 1 and 2. Overall mortality among patients with the highest proBNP values on day 1 was 30.6% compared with 63% in those patients with at least 1 higher value on day 2 to day 7. In patients with a late increase (day 4 to day 7) in proBNP the mortality was 70%, compared with 32.6% in those with proBNP below the value on day 1. Weaning failure was 35% in patients with a late increase and 11.6% in those without a late increase. ProBNP correlated significantly with pulmonary hypertension and cardiac dysfunction before and during ECLS.Conclusions: Absolute proBNP values are associated with weaning failure but not overall mortality in neonates with congenital diaphragmatic hernia undergoing ECLS. Echocardiographic findings correlate well with proBNP values. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
25. Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection.
- Author
-
Wagner, Karolin I., Mateyka, Laura M., Jarosch, Sebastian, Grass, Vincent, Weber, Simone, Schober, Kilian, Hammel, Monika, Burrell, Teresa, Kalali, Behnam, Poppert, Holger, Beyer, Henriette, Schambeck, Sophia, Holdenrieder, Stefan, Strötges-Achatz, Andrea, Haselmann, Verena, Neumaier, Michael, Erber, Johanna, Priller, Alina, Yazici, Sarah, and Roggendorf, Hedwig
- Abstract
T cell immunity is crucial for control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and has been studied widely on a quantitative level. However, the quality of responses, in particular of CD8
+ T cells, has only been investigated marginally so far. Here, we isolate T cell receptor (TCR) repertoires specific for immunodominant SARS-CoV-2 epitopes restricted to common human Leukocyte antigen (HLA) class I molecules in convalescent individuals. SARS-CoV-2-specific CD8+ T cells are detected up to 12 months after infection. TCR repertoires are diverse, with heterogeneous functional avidity and cytotoxicity toward virus-infected cells, as demonstrated for TCR-engineered T cells. High TCR functionality correlates with gene signatures that, remarkably, could be retrieved for each epitope:HLA combination analyzed. Overall, our data demonstrate that polyclonal and highly functional CD8+ TCRs—classic features of protective immunity—are recruited upon mild SARS-CoV-2 infection, providing tools to assess the quality of and potentially restore functional CD8+ T cell immunity. [Display omitted] • SARS-CoV-2-specific CD8+ T cells are detectable up to 12 months after infection • scRNA sequencing reveals polyclonal CD8+ T cells with variable functionalities • High-avidity CD8+ T cells engineered with SARS-CoV-2-specific TCRs are cytotoxic • Single cell signature for highly functional SARS-CoV-2-specific CD8+ T cells Wagner et al. detect CD8+ T cell responses to diverse immunodominant SARS-CoV-2-specific epitopes. scRNA sequencing of epitope-responsive CD8+ T cells reveals a polyclonal T cell receptor repertoire. State-of-the-art TCR re-expression confirms a highly specific and functional T cell response in convalescent mild COVID-19. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
26. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer
- Author
-
Holdenrieder, Stefan, von Pawel, Joachim, Dankelmann, Elke, Duell, Thomas, Faderl, Bernhard, Markus, Andreas, Siakavara, Maria, Wagner, Horst, Feldmann, Knut, Hoffmann, Harald, Raith, Hannelore, Nagel, Dorothea, and Stieber, Petra
- Subjects
- *
LUNG cancer treatment , *CANCER chemotherapy , *TUMOR markers , *CANCER patients , *DRUG efficacy , *CLINICAL pathology - Abstract
Summary: The increasing panel of systemic therapies enables the individual management of cancer patients, even in advanced stages. However, diagnostic tools indicating early the efficacy of therapy are still needed. In prospectively collected sera of 161 patients with recurrent non-small cell lung cancer (NSCLC) receiving second-line chemotherapy, the courses of nucleosomes, cytokeratin-19 fragments (CYFRA 21-1), carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and progastrin-releasing peptide (ProGRP) were investigated and correlated with therapy response. At high specificity for detection of progressive disease, most sensitive biomarkers were identified and included in a combination model. High levels and insufficient decreases of nucleosomes and CYFRA 21-1 during the first cycle of therapy indicated poor outcome. Combination of nucleosome concentrations at day 8 and CYFRA 21-1 before start of the second cycle enabled the early detection of progressive disease with a sensitivity of 34.4% at 95% specificity (AUC 0.79) prior to imaging techniques. When cutoffs were fixed at the 90th percentile of responding patients, the combination model achieved sensitivities of 19% at 100% specificity and of 52% at 88% specificity. Thus, nucleosomes and CYFRA 21-1 showed to be valuable for the individual management of patients with recurrent NSCLC. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
27. Does brain specific 24S-hydroxycholesterol in plasma indicate the disruption of the blood–brain barrier in patients with ischemic stroke?
- Author
-
Holdenrieder, Stefan, Lütjohann, Dieter, Geiger, Sandra, von Bergmann, Klaus, Stieber, Petra, and Hamann, Gerhard F.
- Subjects
- *
CHOLESTEROL , *ISCHEMIA , *BLOOD circulation disorders , *PATIENTS - Abstract
Determination of plasma 24S-hydroxycholesterol, which is produced almost exclusively in the brain and is released only in small amounts into circulation under physiological conditions, might be a marker to monitor non-invasively the time course and the extent of the disintegration of the blood–brain barrier after cerebral ischemia. We investigated the plasma concentrations for 4 to 10 days of 24S-hydroxycholesterol, and compared the concentration with the liver-specific oxysterol 7α-hydroxycholesterol, the ubiquitously produced 27-hydroxycholesterol, and cholesterol itself in six patients who were admitted to the hospital within 24h after symptoms of stroke. Quantification of oxysterols was performed by isotope dilution mass spectrometry and cholesterol by gas–liquid chromatography. Initial concentrations of cholesterol, 24S-, 7α-, and 27-hydroxycholesterol in stroke patients were not different from data of healthy controls given in the literature. During the following days, no changes could be observed in the concentrations of cholesterol nor in the other oxysterols. Particularly the brain specific 24S-hydroxycholesterol was very constant and showed only minimal changes. Furthermore, comparison of patients with extended or small lesions did not reveal any differences in the concentrations of oxysterols. Therefore, circulating levels of 24S-hydroxycholesterol are supposed to be only of limited value for monitoring the brain–blood barrier function in patients with acute ischemic stroke. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
28. Elevated plasma myeloperoxidase concentration in adults with obesity
- Author
-
Zur, Berndt, Look, Markus, Holdenrieder, Stefan, and Stoffel-Wagner, Birgit
- Published
- 2011
- Full Text
- View/download PDF
29. Early postnatal changes of circulating N-terminal-pro-B-type natriuretic peptide in neonates with congenital diaphragmatic hernia.
- Author
-
Heindel, Katrin, Holdenrieder, Stefan, Patel, Neil, Bartmann, Peter, Schroeder, Lukas, Berg, Christoph, Merz, Waltraut Maria, Mueller, Andreas, and Kipfmueller, Florian
- Subjects
- *
DIAPHRAGMATIC hernia , *NEWBORN infants , *PULMONARY hypertension , *NEWBORN screening , *ANTHRACYCLINES , *BLOOD coagulation factor XIII , *PEPTIDE hormones , *RISK assessment - Abstract
Background: Severity of lung hypoplasia, pulmonary hypertension (PH) and cardiac dysfunction are major contributors to mortality in congenital diaphragmatic hernia (CDH). Therefore, early assessment and management is important to improve outcome. NT-proBNP is an established cardiac biomarker with only limited data for early postnatal risk assessment in CDH newborns.Aims: To investigate the correlation of NT-proBNP at birth, 6 h, 12 h, 24 h, and 48 h with PH and cardiac dysfunction and the prognostic information of NT-proBNP for the use of ECMO support or mortality.Subjects: 44 CDH newborns treated at our institution (December 2014-October 2017) were prospectively enrolled.Outcome Measures: Primary clinical endpoint was either need for ECMO or death within the first 48 h (group A). Infants not receiving ECMO support were allocated to group B. Mortality was tested as secondary endpoint.Results: NT-proBNP levels measured at 6 h, 12 h, 24 h and 48 h postpartum correlated significantly with PH severity following NICU admission and at 24 h, and with severity of cardiac dysfunction at birth, 24 h, 48 h and after 7 days of life. There was no difference in NT-proBNP levels between survivors and non-survivors. NT-proBNP levels were significantly higher in group A at 6 h (p = 0.007), 12 h (p = 0.036), and 24 h (p = 0.007), but not at birth (p = 0.785) or 48 h (p = 0.15) compared to group B.Conclusion: NT-proBNP analysis in the first 48 h of life may be useful to assess PH and cardiac dysfunction in CDH newborns and to predict the need for ECMO support. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
30. Systemic inflammatory response syndrome in patients undergoing transcatheter aortic valve implantation.
- Author
-
Syryca, Finn, Pellegrini, Costanza, Rheude, Tobias, Zobel, Florian, Kornhuber, Katharina, Xhepa, Erion, Mayr, N. Patrick, Alvarez-Covarrubias, Hector A., Holdenrieder, Stefan, Schunkert, Heribert, Thilo, Christian, Kastrati, Adnan, and Joner, Michael
- Subjects
- *
HEART valve prosthesis implantation , *SYSTEMIC inflammatory response syndrome , *AORTIC stenosis , *AORTIC valve insufficiency - Abstract
Data on systemic inflammatory response syndrome (SIRS) after transcatheter aortic valve implantation (TAVI) are scarce and limited to small cohorts. We aimed to investigate its incidence and mid-term impact in a large cohort of TAVI patients. From January 2018 to December 2020, 717 patients with severe aortic valve stenosis undergoing TAVI were included. SIRS was defined as fulfilling at least two of the following criteria within 48 h from the procedure: leucocyte count >12.0 or <4.0 × 109/l, respiratory rate > 20 breaths per minute or PaCO 2 ≤ 4.3 kPa/32 mmHg, heart rate > 90 beats per minute and temperature > 38.0 °C or <36.0 °C. Clinical endpoints were 1-year rehospitalization for chronic heart failure (CHF) and 2-years all-cause mortality. Event rates during follow-up were calculated as Kaplan-Meier estimates. SIRS developed in 56.3 % (404/717) of patients after TAVI. SIRS occurred more frequently in patients with post-dilatation (SIRS 34.7 % (140/404) vs. no SIRS 23.3 % (73/313); p < 0.001) and major vascular complications (SIRS 16.1 % (65/404) vs. no SIRS 8.6 % (27/313); p = 0.004). Further, ICU days were more in patients who developed SIRS (SIRS 1.56 ± 1.50 days vs. no SIRS 1.22 ± 1.02 days; p = 0.001). At 2-years, all-cause mortality in the entire population was 23.9 %. However, there was no difference in CHF at 1-year (5.9 % vs. 4.1 %; log-rank = 0.347) nor in all-cause mortality at 2-years (22.0 % vs. 26.2 %; log-rank = 0.690) between the groups. SIRS is a common finding after TAVI, which may prolong hospital stay but is without effect on mortality during 2-years follow-up. • SIRS is a common finding after TAVI, occurring in more than half of patients. • SIRS occurs more often in patients with post-dilatation and major vascular complications. • Inflammatory markers after TAVI increase, irrespective of SIRS development. • The occurrence of SIRS after TAVI is without effect on 2-years mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. MA11.09 Progastrin-Releasing Peptide (ProGRP) to Rule out Progressive Disease in Patients with Small Cell Lung Carcinoma (SCLC).
- Author
-
Muley, Thomas, Zhang, Xiaotong, Holdenrieder, Stefan, Korse, Catharina, Zhi, Xiuyi, Molina, Rafael, Liu, Zhongjuan, Hartmann, Gunther, Van Den Heuvel, Michel, Qian, Kun, Marrades, Ramon, Engel, Christine, He, Ying, Wehnl, Birgit, Dayyani, Farshid, and Herth, Felix Jf
- Published
- 2017
- Full Text
- View/download PDF
32. Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy.
- Author
-
Lehner, Julia, Stötzer, Oliver J., Fersching, Debora, Nagel, Dorothea, and Holdenrieder, Stefan
- Subjects
- *
BLOOD plasma , *BREAST cancer surgery , *BIOMARKERS , *DNA analysis , *HEALTH outcome assessment , *HISTOPATHOLOGY ,BREAST cancer chemotherapy - Abstract
Abstract: Background: In breast cancer patients undergoing neoadjuvant chemotherapy before surgery, biomarkers for predicting response to therapy are urgently required. Patients and methods: In 65 patients with locally confined breast cancer who had completed the course of chemotherapy until surgery, plasma DNA biomarkers obtained before and during therapy were evaluated concerning (early) estimation of therapy response. Levels of repetitive ALU 115 and ALU 247 elements as well as DNA integrity calculated according the formulas of Umetani (1) and Wang (2) were correlated with changes in histopathological staging at surgery and compared with conventional tumor markers CEA and CA 15-3. Results: At surgery, 13 patients presented complete remission (CR), 32 partial remission (PR) and 20 no change of disease (NC). Pretherapeutic Her2/neu status was positively correlated with therapy response (p =0.019). DNA biomarkers before onset of therapy cycles 1, 2 and 6 did not indicate outcome after therapy. However, kinetics of ALU 115 from cycle 1 to 6 showed decreases in CR patients, while in NC patients, an increase was observed (p =0.033). Similar tendencies were found for ALU 247 fragments. DNA integrity index as well as CEA and CA 15-3 were not informative for therapy outcome. Conclusion: Kinetics of plasma DNA (ALU 115) is associated with response to neoadjuvant chemotherapy in patients with locally confined breast cancer. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
33. Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin.
- Author
-
Stoetzer, Oliver J., Fersching, Debora M.I., Salat, Christoph, Steinkohl, Oliver, Gabka, Christian J., Hamann, Ulrich, Braun, Michael, Feller, Axel-Mario, Heinemann, Volker, Siegele, Barbara, Nagel, Dorothea, and Holdenrieder, Stefan
- Subjects
- *
ADJUVANT treatment of cancer , *BREAST cancer patients , *BREAST cancer treatment , *CANCER chemotherapy , *BIOMARKERS , *APOPTOSIS , *CHROMATIN , *SURVIVIN (Protein) - Abstract
Highlights: [•] Circulating nucleosomes and survivin are elevated in sera of patients with locally confined and metastatic breast cancer. [•] Cytokeratin-18 fragments (M30-antigen) and breast tumor markers CEA and CA 15-3 are only elevated in metastatic disease. [•] High pretherapeutic nucleosome levels indicate poor response to neoadjuvant chemotherapy. [•] Apoptotic biomarkers bear valuable information for diagnosis and therapy response in breast cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.